Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.93
-0.26 (-2.32%)
May 26, 2026, 2:36 PM EDT - Market open

Keros Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
281.5287.42559.93331.15279.05230.04
Cash & Short-Term Investments
281.5287.42559.93331.15279.05230.04
Cash Growth
-60.93%-48.67%69.09%18.67%21.30%-13.48%
Accounts Receivable
0.43.572.740.14-18
Other Receivables
2.252.25----
Total Trade Receivables
2.655.822.740.14-18
Other Current Assets
6.5322.226.22166.723.4
Total Current Assets
290.68315.43588.89347.29285.77251.44
Net Property, Plant & Equipment
20.1721.1423.4919.4717.572.4
Other Long-Term Assets
1.451.453.513.263.451.41
Total Assets
312.29338.02615.89370.03306.78255.25
Accounts Payable
1.491.974.65.453.343.65
Accrued Expenses
8.8616.0420.8717.9212.757.34
Current Portion of Leases
2.52.411.981.010.460.86
Total Current Liabilities
12.8520.4127.4524.3716.5511.85
Long-Term Leases
13.8114.4816.8813.4412.810.23
Total Long-Term Liabilities
13.8114.4816.8813.4412.810.23
Total Liabilities
26.6634.8944.3337.8129.3612.08
Common Stock
000000
Treasury Stock
-384.56-384.56----
Additional Paid-in Capital
1,1761,1691,140713.64505.86366.93
Retained Earnings
-505.47-481.77-568.78-381.43-228.43-123.76
Shareholders' Equity
285.63303.13571.55332.21277.42243.17
Total Liabilities & Equity
312.29338.02615.89370.03306.78255.25
Total Debt
16.3116.8818.8614.4413.271.09
Net Cash (Debt)
265.19270.53541.07316.7265.78228.95
Net Cash Growth
-1.98%-50.00%70.84%19.16%16.09%-13.60%
Net Cash Per Share
8.287.1514.4510.7610.539.81
Book Value
285.63303.13571.55332.21277.42243.17
Book Value Per Share
8.928.0115.2711.2810.9910.42
Tangible Book Value
285.63303.13571.55332.21277.42243.17
Tangible Book Value Per Share
8.928.0115.2711.2810.9910.42
Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q